Vest Financial LLC Acquires 1,271 Shares of Bristol-Myers Squibb (NYSE:BMY)

Vest Financial LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 15.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,746 shares of the biopharmaceutical company’s stock after buying an additional 1,271 shares during the period. Vest Financial LLC’s holdings in Bristol-Myers Squibb were worth $551,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BMY. Cidel Asset Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 5.7% in the fourth quarter. Cidel Asset Management Inc. now owns 20,980 shares of the biopharmaceutical company’s stock valued at $1,187,000 after purchasing an additional 1,133 shares in the last quarter. Capital Management Associates Inc purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $226,000. Shepherd Financial Partners LLC lifted its position in shares of Bristol-Myers Squibb by 4.7% during the 4th quarter. Shepherd Financial Partners LLC now owns 9,428 shares of the biopharmaceutical company’s stock worth $533,000 after buying an additional 423 shares in the last quarter. Realta Investment Advisors purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $451,000. Finally, Golden State Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $199,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $56.96 on Monday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.10. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The stock has a market cap of $115.51 billion, a P/E ratio of -12.89, a P/E/G ratio of 2.13 and a beta of 0.45. The company has a 50 day moving average of $57.56 and a 200 day moving average of $53.83.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.35%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is -56.11%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Truist Financial boosted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday. Morgan Stanley raised their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Finally, Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.